Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression

Open access
Fousek, Kristen, Watanabe, Junji, Joseph, Sujith K., George, Ann, An, Xingyue, Byrd, Tiara T., Morris, Jessica S., Luong, Annie, Martínez-Paniagua, Melisa A., Sanber, Khaled, Navai, Shoba A., Gad, Ahmed Z., Salsman, Vita S., Mathew, Pretty R., Kim, Hye Na, Wagner, Dimitrios L., Brunetti, Lorenzo, Jang, Albert, Baker, Matthew L., Varadarajan, Navin, Hegde, Meenakshi, Kim, Yong-Mi, Heisterkamp, Nora, Abdel-Azim, Hisham, Ahmed, Nabil · 2021 · Leukemia

Abstract

Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(−) disease. We report that CD19(−) escape is associated with downregulation, but preservation, of targetable expression of CD20 and CD22. Accordingly, we reasoned that broadening the spectrum of CD19CAR T-cells to include both CD20 and CD22 would enable them to target CD19(−) escape BL-ALL while preserving their upfront efficacy. We created a CD19/20/22-targeting CAR T-cell by coexpressing individual CAR molecules on a single T-cell using one tricistronic transgene. CD19/20/22CAR T-cells killed CD19(−) blasts from patients who relapsed after CD19CAR T-cell therapy and CRISPR/Cas9 CD19 knockout primary BL-ALL both in vitro and in an animal model, while CD19CAR T-cells were ineffective. At the subcellular level, CD19/20/22CAR T-cells formed dense immune synapses with target cells that mediated effective cytolytic complex formation, were efficient serial killers in single-cell tracking studies, and were as efficacious as CD19CAR T-cells against primary CD19(+) disease. In conclusion, independent of CD19 expression, CD19/20/22CAR T-cells could be used as salvage or front-line CAR therapy for patients with recalcitrant disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-020-0792-2

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 182

Metadata

Authors
Fousek, K., Watanabe, J., Joseph, S. K., George, A., An, X., Byrd, T. T., Morris, J. S., Luong, A., Martínez-Paniagua, M. A., Sanber, K., Navai, S. A., Gad, A. Z., Salsman, V. S., Mathew, P. R., Kim, H. N., Wagner, D. L., Brunetti, L., Jang, A., Baker, M. L., Varadarajan, N., Hegde, M., Kim, Y.-M., Heisterkamp, N., Abdel-Azim, H., & Ahmed, N.
Venue
Leukemia
Published
2020-03-24
Volume
35
Issue
1
Pages
75-89
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W3012942658
Cited by
182
References
6
FWCI
10.35
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. https://app.cochat.ai/papers/10.1038/s41375-020-0792-2
The paper
Fousek, K., Watanabe, J., Joseph, S. K., George, A., An, X., Byrd, T. T., Morris, J. S., Luong, A., Martínez-Paniagua, M. A., Sanber, K., Navai, S. A., Gad, A. Z., Salsman, V. S., Mathew, P. R., Kim, H. N., Wagner, D. L., Brunetti, L., Jang, A., Baker, M. L., . . . Ahmed, N. (2021). CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. https://doi.org/10.1038/s41375-020-0792-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.